Denosumab  	Denosumab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
osteoporotic  	osteoporotic  	 JJ	B-NP
fractures  	fractures  	 NN	I-NP
in  	in  	 IN	O
postmenopausal  	postmenopausal  	 JJ	B-NP
women  	women  	 NNS	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
denosumab  	denosumab  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
osteoporotic  	osteoporotic  	 JJ	B-NP
fractures  	fractures  	 NN	I-NP
in  	in  	 IN	O
postmenopausal  	postmenopausal  	 JJ	B-NP
women 	women 	 NNS	I-NP
.  	.  	 .	O
Denosumab  	Denosumab  	 NNP	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
large  	large  	 JJ	O
randomised  	randomised  	 JJ	B-NP
trial  	trial  	 NN	I-NP
to  	to  	 TO	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
frequency  	frequency  	 NN	O
of  	of  	 IN	O
osteoporotic  	osteoporotic  	 JJ	B-NP
fractures  	fractures  	 NN	I-NP
when  	when  	 WRB	O
given  	given  	 VBN	O
subcutaneously  	subcutaneously  	 VBN	O
at  	at  	 IN	O
6-monthly  	6-monthly  	 CD	O
intervals 	intervals 	 NNS	O
.  	.  	 .	O
Compared  	Compared  	 VBN	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
relative  	relative  	 JJ	B-NP
risks  	risks  	 NNS	I-NP
of  	of  	 IN	I-NP
clinical  	clinical  	 JJ	I-NP
vertebral  	vertebral  	 NN	I-NP
and  	and  	 CC	O
hip  	hip  	 JJ	O
fractures  	fractures  	 NN	O
were  	were  	 VBD	O
0.32  	0.32  	 CD	O
and  	and  	 CC	O
0.60 	0.60 	 CD	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
vertebral  	vertebral  	 NNS	I-NP
fractures  	fractures  	 VBP	O
occurred  	occurred  	 VBN	O
in  	in  	 IN	O
0.8 	0.8 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
women  	women  	 NNS	O
taking  	taking  	 VBG	O
denosumab  	denosumab  	 NNS	B-NP
and  	and  	 CC	O
2.6 	2.6 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
control  	control  	 NN	B-NP
subjects 	subjects 	 NNS	I-NP
.  	.  	 .	O
Hip  	Hip  	 NNP	B-NP
fractures  	fractures  	 VBD	O
occurred  	occurred  	 VBN	O
in  	in  	 IN	O
1.2 	1.2 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
women  	women  	 NNS	O
on  	on  	 IN	O
placebo  	placebo  	 NN	O
and  	and  	 CC	O
0.7 	0.7 	 CD	O
%  	%  	 NN	O
on  	on  	 IN	O
denosumab 	denosumab 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
expected  	expected  	 JJ	O
use  	use  	 NN	O
is  	is  	 VBZ	O
in  	in  	 IN	O
women  	women  	 NNS	O
who  	who  	 WP	O
cannot  	cannot  	 RB	O
tolerate  	tolerate  	 VB	O
oral  	oral  	 JJ	B-NP
bisphosphonates 	bisphosphonates 	 NN	I-NP
.  	.  	 .	O
Other  	Other  	 JJ	O
options  	options  	 NNS	O
in  	in  	 IN	O
that  	that  	 DT	O
situation  	situation  	 NN	O
include  	include  	 VBP	O
strontium  	strontium  	 JJ	B-NP
ranelate  	ranelate  	 NN	I-NP
and  	and  	 CC	O
zoledronate 	zoledronate 	 NN	B-NP
,  	,  	 ,	O
which 	which 	 WDT	O
,  	,  	 ,	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
also  	also  	 RB	O
reduced  	reduced  	 VBN	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
vertebral  	vertebral  	 JJ	I-NP
fractures  	fractures  	 NNS	I-NP
[ 	[ 	 -LRB-	O
relative  	relative  	 JJ	B-NP
risk  	risk  	 NN	I-NP
( 	( 	 -LRB-	O
RR 	RR 	 NNP	B-NP
)  	)  	 -RRB-	O
0.65  	0.65  	 NNP	O
and  	and  	 CC	O
0.23 	0.23 	 CD	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
] 	] 	 -RRB-	O
.  	.  	 .	O
Zoledronate  	Zoledronate  	 NNP	B-NP
also  	also  	 RB	O
significantly  	significantly  	 RB	O
reduced  	reduced  	 VBN	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
hip  	hip  	 JJ	O
fractures  	fractures  	 NNS	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
0.59 	0.59 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
concluded  	concluded  	 VBD	O
that  	that  	 DT	O
zoledronate  	zoledronate  	 NN	B-NP
was  	was  	 VBD	O
the  	the  	 DT	O
main  	main  	 JJ	O
comparator 	comparator 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
relative  	relative  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 NN	I-NP
of  	of  	 IN	I-NP
denosumab  	denosumab  	 NN	I-NP
and  	and  	 CC	O
zoledronate  	zoledronate  	 NN	B-NP
depends  	depends  	 VBZ	O
mainly  	mainly  	 RB	O
on  	on  	 IN	O
assumptions  	assumptions  	 NNS	O
about  	about  	 IN	O
costs  	costs  	 NNS	O
of  	of  	 IN	O
administration 	administration 	 NN	B-NP
.  	.  	 .	O
